SEARCH RESULTS

381 RESULTS

DNL343

THERAPEUTICS Denali Therapeutics Inc. Small Molecule Other In February 2020, Denali began a Phase 1 trial testing single and multiple ascending oral doses of DNL343 in 88 healthy adults. The primary outcomes are safety and plasma pharmacokinetics measured up to 20 day

Current Filters

  • Date Range : Sep 2020 to Sep 2020 x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE